Why the study?
Do RAAS blockers have beneficial effects for cardiovascular disease in chronic kidney disease patients undergoing hemodialysis?
Do RAAS blockers have beneficial effects for cardiovascular disease in chronic kidney disease patients undergoing hemodialysis?
This review discusses the effects of RAAS blockers on cardiovascular disease in patients with chronic kidney disease undergoing hemodialysis.
Effects of RAAS blockers on CVD in hemodialysis CKD patients remain uncertain; leaves open need for dedicated RCTs.
The renin-angiotensin-aldosterone system (RAAS) blockers have been widely used in chronic kidney disease patients undergoing hemodialysis; however, whether RAAS blockers have beneficial effects for cardiovascular disease in those patients has not been fully defined. This review focuses on the effects of RAAS blockers in chronic kidney disease undergoing hemodialysis for cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Morishita et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: